Key result
2017 ACC/AHA guidelines more than double estimated hypertension prevalence in Peru to ~32%.
Why the study?
The 2017 ACC/AHA hypertension guideline redefined hypertension thresholds, potentially increasing prevalence estimates and treatment eligibility, necessitating updated national estimates for Peru to inform public health planning.
Does the application of the 2017 ACC/AHA hypertension guidelines increase the estimated prevalence of hypertension compared to JNC7 guidelines in Peruvian adults?
Cross-Sectional (n=32,514)
Does the application of the 2017 ACC/AHA hypertension guidelines increase the estimated prevalence of hypertension compared to JNC7 guidelines in Peruvian adults?
Answers are grounded in this paper and cite their sources.
Adoption of the 2017 ACC/AHA hypertension guidelines in Peru would increase the estimated prevalence of hypertension from 13.6% to 31.5%, highlighting a major public health challenge given the high proportion of individuals lacking access to routine blood pressure measurements.
In 2017, the American College of Cardiology/American Heart Association (ACC/AHA) recommended a new categorisation for blood pressure levels. The previous guideline (Joint National Committee 7, 2017; JNC7) defined hypertension as a systolic blood pressure (SBP) of 140 mmHg or greater and/or a diastolic blood pressure (DBP) of 90 mmHg or greater.1 The new 2017 ACC/AHA guideline has changed the definition of hypertension as a SBP of 130 mmHg or greater and/or a DBP of 80 mmHg or greater, reducing SBP and DBP by 10 mmHg each.1 Recommendations for treatment initiation were also modified in this guideline, as making positive lifestyle changes and initiating treatment earlier in disease development may help prevent cardiovascular disease (CVD) progression and reduce the risks and complications of hypertension. Application of this revised definition could lead to significant increases in both the number of people considered to have hypertension and eligibility for treatment and more intensive care. The benefit of this would be potentially to catch individuals earlier in disease progression and reduce cardiovascular morbidity and mortality.1 This new evidence-based recommendation has prompted researchers to estimate an updated prevalence of hypertension; a growing body of literature has recognised the importance of the adjusted definition.2–5 The implications of this new guideline highlight the importance of having revised estimates for all countries to aid public health resource planning and prevention strategies, as the prevalence of hypertension varies by region. Many countries have undertaken large-scale health surveys and epidemiological studies that include measures of cardiovascular risk factors.5 Thus using data from accurate, nationally representative sources seems to be a useful way of retrieving information to tackle this relevant problem in public health. The Demographic and Family Health Survey – ENDES – is one of the most important statistical research studies carried out continuously in Peru. We conducted a cross-sectional analytical study using data from ENDES 2017, which is nationally representative for individuals 15 years and older (N = 32,514). Hypertension was considered as the main study variable according to the cut-off points of the JNC7 and 2017 ACC/AHA. Blood pressure was measured twice in each person and the mean value between both measurements was calculated. In addition, the weighted prevalence of hypertension was estimated according to sociodemographic characteristics of the population: age, sex, diabetes, education, household wealth status, place of residence and region. We also obtained the proportion of the hypertensive population that responded in the survey not having blood pressure measurements (BPMs) by a health professional (medical doctor, nurse, health promoter, etc.) in the past 12 months (no BPM12). Table 1 shows hypertensive prevalence according to both guidelines, the proportion of hypertensive people who reported no BPM12, and absolute differences in hypertension prevalence comparing the 2017 ACC/AHA and JNC7 guidelines. Among 32,514 participants aged 15 years and older, the estimated prevalence of hypertension was 31.5% (95% confidence interval (CI) 30.6–32.5%) according to the 2017 ACC/AHA guidelines, 17.9% higher than the estimate under previous guidelines (13.6%, 95% CI 12.9–14.3%). Weighted prevalence, blood pressure measurements and absolute changes in prevalence according to JNC7 and 2017 ACC/AHA guidelines. JNC7: Joint National Committee 7, 2017; ACC/AHA: American College of Cardiology/American Heart Association; BPM: blood pressure measurement; CI: confidence interval; No BPM12: no blood pressure measurement in the last 12 months. Weighted prevalence, blood pressure measurements and absolute changes in prevalence according to JNC7 and 2017 ACC/AHA guidelines. JNC7: Joint National Committee 7, 2017; ACC/AHA: American College of Cardiology/American Heart Association; BPM: blood pressure measurement; CI: confidence interval; No BPM12: no blood pressure measurement in the last 12 months. In addition, we found that the adoption of the guidelines would lead to the classification of 40.2% of men (95% CI 38.8–41.5%) and 23.1% of women (95% CI 22.0–24.3%) as having hypertension. The differences observed with JNC7 is over 15% in most categories. Within people with comorbid diabetes, and age 65 years and older new guidelines would present greater than 50% prevalence of hypertension. The most striking result to emerge from the data is that the hypertensive population without BPM12 would increase from 42.2% to 48.9%. Interestingly, in some groups the difficulties in access will be greatly expanded with the new guidelines, such us younger groups, men, the poorest and those from a rural setting in which the proportion would be over 50%. The evidence from this study suggests that the new guidelines are extraordinarily aggressive, essentially classifying one third of adult Peruvians as having hypertension. They call for people in this new category to have a repeat blood pressure evaluation within 3–6 months in a country that is faced with a problem such as primary prevention regarding access to BPMs by a health professional. In this regard, a recent review6 raised the point that one of the major challenges in BPMs is to extend the use of out-of-office measurements (either home BPMs or 24-hour ambulatory BPMs). Action points to improve them that should be implemented in Peru include: accurate patient instruction; train practitioners and increase financial resources. Peru has unmet needs in awareness, treatment and control of hypertension. Particular challenges are lack of awareness of hypertension in rural areas, and poor levels of treatment and control among people who have migrated from rural to urban areas.7 Furthermore, like many other developing countries, Peru is facing a double burden of infectious and non-communicable diseases that warrants national awareness and control programmes.8 Data from surveys such as ENDES in Peru show that large proportions of patients at high CVD risk have unhealthy lifestyle habits and uncontrolled blood pressure. In coincidence with data published in 14 European countries (EUROASPIRE IV)9 it is clear that more efforts must be taken to improve cardiovascular prevention in people at high CVD risk. We think that our findings could be useful for decision-makers because in our view these results are an excellent initial step towards identifying groups that will benefit most from developing effective prevention and control methods in Peru. Besides this, we recommend conducting more comprehensive population-based studies to estimate the recent burden and implications of hypertension in Peru. Our results, like previous findings in other countries,3, 4 support the need for public health programmes to increase awareness and minimise complications of hypertension. In summary, our work indicates that a significant proportion of the adults in Peru may have hypertension according to the latest guidelines but do not have access to BPMs by a health professional. Considering the morbidity and mortality associated with hypertension, this condition is a major public health challenge for Peru and other countries with similar sociodemographic characteristics. The author(s) declared no potential conflicts of interest with respect to the research, authorship, and/or publication of this article. The author(s) received no financial support for the research, authorship, and/or publication of this article.
No takes yet. Share an insight, caveat, or question.
Hernández‐Vásquez et al. (2018) conducted a cross-sectional in Hypertension (n=32,514). 2017 ACC/AHA hypertension guidelines vs. JNC7 guidelines was evaluated on Prevalence of hypertension. Applying the 2017 ACC/AHA guidelines increased the estimated prevalence of hypertension in Peru to 31.5% compared to 13.6% under the previous JNC7 guidelines.
Synapse has enriched 10 related papers. Consider them for comparative context: